These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial. Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149 [TBL] [Abstract][Full Text] [Related]
3. New drugs and perspectives for new anti-tuberculosis regimens. Tiberi S; Muñoz-Torrico M; Duarte R; Dalcolmo M; D'Ambrosio L; Migliori GB Pulmonology; 2018; 24(2):86-98. PubMed ID: 29487031 [TBL] [Abstract][Full Text] [Related]
4. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB). Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909 [TBL] [Abstract][Full Text] [Related]
7. Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance. Lohrasbi V; Talebi M; Bialvaei AZ; Fattorini L; Drancourt M; Heidary M; Darban-Sarokhalil D Tuberculosis (Edinb); 2018 Mar; 109():17-27. PubMed ID: 29559117 [TBL] [Abstract][Full Text] [Related]
8. Synthetic investigational new drugs for the treatment of tuberculosis. Kwon YS; Koh WJ Expert Opin Investig Drugs; 2016; 25(2):183-93. PubMed ID: 26576631 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany. Wirth D; Dass R; Hettle R BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207 [TBL] [Abstract][Full Text] [Related]
10. Recent updates on drug resistance in Mycobacterium tuberculosis. Singh R; Dwivedi SP; Gaharwar US; Meena R; Rajamani P; Prasad T J Appl Microbiol; 2020 Jun; 128(6):1547-1567. PubMed ID: 31595643 [TBL] [Abstract][Full Text] [Related]
11. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs. Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149 [TBL] [Abstract][Full Text] [Related]
12. Therapy of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. Seaworth BJ; Griffith DE Microbiol Spectr; 2017 Mar; 5(2):. PubMed ID: 28361737 [TBL] [Abstract][Full Text] [Related]
13. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB? Dheda K; Cox H; Esmail A; Wasserman S; Chang KC; Lange C Respirology; 2018 Jan; 23(1):36-45. PubMed ID: 28850767 [TBL] [Abstract][Full Text] [Related]
14. Drug-resistant tuberculosis: An update on disease burden, diagnosis and treatment. Lange C; Chesov D; Heyckendorf J; Leung CC; Udwadia Z; Dheda K Respirology; 2018 Jul; 23(7):656-673. PubMed ID: 29641838 [TBL] [Abstract][Full Text] [Related]
15. Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings. Sotgiu G; Tiberi S; Centis R; D'Ambrosio L; Fuentes Z; Zumla A; Migliori GB Int J Infect Dis; 2017 Mar; 56():190-193. PubMed ID: 27816662 [TBL] [Abstract][Full Text] [Related]